{"id":"NCT03890367","sponsor":"Sanofi Pasteur, a Sanofi Company","briefTitle":"Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to Two Meningococcal Reference Vaccines in European Toddlers","officialTitle":"Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Versus Nimenrix® or NeisVac-C® in Healthy Toddlers 12 to 23 Months of Age","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-09-12","primaryCompletion":"2020-10-14","completion":"2020-10-14","firstPosted":"2019-03-26","resultsPosted":"2021-10-06","lastUpdate":"2023-09-26"},"enrollment":707,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Meningococcal Immunisation (Healthy Volunteers)"],"interventions":[{"type":"BIOLOGICAL","name":"Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine","otherNames":["MenACYW Conjugate vaccine"]},{"type":"BIOLOGICAL","name":"Meningococcal polysaccharide group A, C, W-135 and Y Conjugate vaccine","otherNames":["Nimenrix®"]},{"type":"BIOLOGICAL","name":"Meningococcal group C polysaccharide Conjugate vaccine adsorbed","otherNames":["NeisVac-C®"]}],"arms":[{"label":"Group 1: MenACYW Conjugate Vaccine","type":"EXPERIMENTAL"},{"label":"Group 2: Nimenrix® Vaccine","type":"ACTIVE_COMPARATOR"},{"label":"Group 3: NeisVac-C® Vaccine","type":"ACTIVE_COMPARATOR"}],"summary":"Primary Objective:\n\nTo demonstrate:\n\n* the non-inferiority of the seroprotection rate (antibody titers greater than or equal to \\[\\>=\\] 1:8) to meningococcal serogroup C following the administration of MenACYW Conjugate or Nimenrix® as measured by serum bactericidal assay using human complement (hSBA). If this non-inferiority was demonstrated, then\n* the non-inferiority of the antibody response (geometric mean titers \\[GMT\\]). If this non-inferiority was demonstrated, then\n* the superiority of the antibody response (GMT). If this superiority was demonstrated, then\n* the superiority of the seroprotection rate.\n\nOr to demonstrate:\n\n* the non-inferiority of the seroprotection rate (antibody titers \\>= 1:8) to meningococcal serogroup C following the administration of MenACYW Conjugate or NeisVac-C® as measured by serum bactericidal assay using baby rabbit complement (rSBA). If this non-inferiority was demonstrated, then\n* the non-inferiority of the antibody response (GMT). If this non-inferiority was demonstrated, then\n* the superiority of the antibody response (GMT).\n\nSecondary Objective:\n\nTo demonstrate:\n\n* the non-inferiority of the seroprotection rate (antibody titers \\>= 1:8) to meningococcal serogroup C following the administration of MenACYW Conjugate vaccine or Nimenrix® as measured by rSBA. If this non-inferiority was demonstrated, then\n* the non-inferiority of the antibody response (GMT). If this non-inferiority was demonstrated, then\n* the superiority of the antibody response (GMT).\n\nOr to demonstrate:\n\n* the non-inferiority of the seroprotection rate (antibody titers \\>= 1:8) to meningococcal serogroup C following the administration of MenACYW Conjugate vaccine or NeisVac-C® as measured by hSBA. If this non-inferiority was demonstrated, then\n* the non-inferiority of the antibody response (GMT). If this non-inferiority was demonstrated, then\n* the superiority of the antibody response (GMT) .","primaryOutcome":{"measure":"Percentage of Participants With Antibody Titers >=1:8 Against Meningococcal Serogroup C Measured by Serum Bactericidal Assay Using Human Complement (hSBA) Following Vaccination With MenACYW Conjugate Vaccine or Nimenrix® (Non-inferiority Analysis)","timeFrame":"Day 30 (post-vaccination)","effectByArm":[{"arm":"Group 1: MenACYW Conjugate Vaccine","deltaMin":99.5,"sd":null},{"arm":"Group 2: Nimenrix® Vaccine","deltaMin":89.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"12 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":16},"locations":{"siteCount":29,"countries":["Denmark","Finland","Germany"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":230},"commonTop":["Irritability","Injection Site Erythema","Injection Site Pain","Crying","Decreased Appetite"]}}